Collegium Pharmaceutical, Inc. Proceeds from Long-term Lines of Credit
Collegium Pharmaceutical, Inc. (COLL) reported Proceeds from Long-term Lines of Credit of $299.50 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Cash Flow › Financing Activities
us-gaap:ProceedsFromLongTermLinesOfCredit · last filed 2026-08-06
- 2026-06-30: Proceeds from Long-term Lines of Credit 6 month $299.50M.
- 2025-06-30: Proceeds from Long-term Lines of Credit 6 month $0.00.
| Period end | Proceeds from Long-term Lines of Credit 6 month |
|---|---|
| 2026-06-30 | $299.50M 10-Q · filed 2026-08-06 |
| 2025-06-30 | $0.00 10-Q · filed 2026-08-06 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Faeth Therapeutics, Inc. (FTH) | United States | $0.750B | |
| Design Therapeutics, Inc. (DSGN) | United States | $0.766B | -12.78 |
| Verastem, Inc. (VSTM) | United States | $0.706B | -1.71 |
| Nuvectis Pharma, Inc. (NVCT) | United States | $0.705B | -17.53 |
| IRONWOOD PHARMACEUTICALS INC (IRWD) | United States | $0.694B | 5.37 |
| Wave Life Sciences, Inc. (WVE) | $0.780B | -5.56 | |
| Olema Pharmaceuticals, Inc. (OLMA) | United States | $0.790B | -5.35 |
| Climb Bio, Inc. (CLYM) | United States | $0.683B | -13.03 |
| Aclaris Therapeutics, Inc. (ACRS) | United States | $0.792B | -9.78 |
| GERON CORP (GERN) | United States | $0.803B | -12.14 |